PharmaTelevision - Remi Delansorne, CEO of Hybrigenics, discusses the upcoming Phase IIb research into prostate cancer treatment

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Remi Delansorne, CEO of Hybrigenics, discusses the upcoming Phase IIb research into prostate cancer treatment

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Remi Delansorne, CEO at Hybrigenics

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Hybrigenics's Products and Clinical studies

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at Bio-Europe in Milan, spring 2011. On this show I have Remi Delansorne , who is a CEO of Hybrigenics based in Paris, France. Welcome to the show.

Remi Delansorne:

Thank you.

Fintan Walton:

Remi, tell us what's happened to Hybrigenics, because Hybrigenics is a well established French company, it's reinvented itself I could describe that it's become a different type of company, so tell us what the recent journey for Hybrigenics has been?

Remi Delansorne:

So we just finished our Phase IIa clinical study of Inecalcitol in prostate cancer in infact castrate-resistant prostate cancer and that's a very interesting study, we just terminated in end of last year and it showed that our compound Inecalcitol is very well tolerated and there is very strong perception of efficacy, in combination with the gold count standard the reference chemotherapy this indication which is Taxotere and now we are preparing for Phase IIb and trying to raise the money needed for Phase IIb because this is a very important indication and the evidence based clinical studies requires now a pretty lot of patients.

Fintan Walton:

Right, so the key thing here is that you've got a product now in Phase II as you say you are going into Phase IIb which is critically important for any biotechnology company like Hybrigenics, so when you talk about doing the Phase IIb you've said it's gonna be a big study so what sort of number, how much money do you need to run a trial like that?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Remi Delansorne

CEO

Remi Delansorne , currently serves as CEO of Hybrigenics based in Paris, France. Remi Delansorne holds a veterinary doctorate from "Ecole Nationale V"t"rinaire d'Alfort" and a PhD in life sciences from Universite Pierre et Marie Curie, Paris. After a post-doctoral fellowship at the University of Texas Medical School in Houston, he joined the pharmaceutical industry in 1985 in Theramex, where he held several positions in pre-clinical R&D. until the company was integrated into the Merck Group (now Merck-Serono) in 2000. In 2002, Remi Delansorne became Merck Global Head of Diabetes Research and responsible for the three preclinical sites in France. Then, he joined Hybrigenics in 2004 as Vice-President for R&D and was appointed CEO of the company in September 2005.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Hybrigenics

Hybrigenics SA is a bio-pharmaceutical group listed (ALHYG) on Alternext (NYSEEuronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics's development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormonerefractory prostate cancer in combination with Sanofi-Aventis'Taxotere, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of oncoproteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer. Hybrigenics Services SAS is a fully-owned subsidiary of Hybrigenics SA, and the market leader in Yeast-Two-Hybrid (Y2H)and related services to identify, validate and inhibit protein interactions for researchers in all areas of life science, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.